Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction

Yasuhiko Sakata; Hiroshi Sato; Kunihiro Kinjo; Kenshi Fujii; Kazuhisa Kodama; Jun Tanouchi; Masayoshi Mishima; Hideo Kusuoka; Daisaku Nakatani; Hiroya Mizuno; Masahiko Shimizu; Masatsugu Hori

doi:10.1159/000089599

Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction

Yasuhiko Sakata, Hiroshi Sato, Kunihiro Kinjo, Kenshi Fujii, Kazuhisa Kodama, Jun Tanouchi, Masayoshi Mishima, Hideo Kusuoka, Daisaku Nakatani, Hiroya Mizuno, Masahiko Shimizu, Masatsugu Hori

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

We conduct a prospective randomized study, the OACIS-LIPID, to determine whether early use of pravastatin can prevent secondary cardiac events in patients with acute myocardial infarction (AMI) and hyperlipidemia (HL). Three hundred and fifty Japanese patients with AMI and mild to moderate HL are randomly assigned to receive or not to receive pravastatin in an open-labeled fashion. The primary dose of pravastatin is 10 mg per day, which is a standard dose for the Japanese population. Both groups receive dietary counseling. Over a 9-month follow-up period, the combination of the endpoints (death, nonfetal myocardial infarction, unstable angina, noncardiac rehospitalization, revascularization and nonfetal stroke) will be evaluated. The results of the OACIS-LIPID study will determine the utility of a practical dose of hydroxymethylglutaryl coenzyme A reductase as an early intervention in AMI.

Original language	English (US)
Pages (from-to)	193-196
Number of pages	4
Journal	HeartDrug
Volume	5
Issue number	4
DOIs	https://doi.org/10.1159/000089599
State	Published - Oct 2005
Externally published	Yes

Keywords

Acute myocardial infarction
Statin

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1159/000089599

Cite this

@article{20bec85b63cb47f4868f7cdcec6b885e,

title = "Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction",

abstract = "We conduct a prospective randomized study, the OACIS-LIPID, to determine whether early use of pravastatin can prevent secondary cardiac events in patients with acute myocardial infarction (AMI) and hyperlipidemia (HL). Three hundred and fifty Japanese patients with AMI and mild to moderate HL are randomly assigned to receive or not to receive pravastatin in an open-labeled fashion. The primary dose of pravastatin is 10 mg per day, which is a standard dose for the Japanese population. Both groups receive dietary counseling. Over a 9-month follow-up period, the combination of the endpoints (death, nonfetal myocardial infarction, unstable angina, noncardiac rehospitalization, revascularization and nonfetal stroke) will be evaluated. The results of the OACIS-LIPID study will determine the utility of a practical dose of hydroxymethylglutaryl coenzyme A reductase as an early intervention in AMI.",

keywords = "Acute myocardial infarction, Statin",

author = "Yasuhiko Sakata and Hiroshi Sato and Kunihiro Kinjo and Kenshi Fujii and Kazuhisa Kodama and Jun Tanouchi and Masayoshi Mishima and Hideo Kusuoka and Daisaku Nakatani and Hiroya Mizuno and Masahiko Shimizu and Masatsugu Hori",

year = "2005",

month = oct,

doi = "10.1159/000089599",

language = "English (US)",

volume = "5",

pages = "193--196",

journal = "HeartDrug",

issn = "1422-9528",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction

AU - Sakata, Yasuhiko

AU - Sato, Hiroshi

AU - Kinjo, Kunihiro

AU - Fujii, Kenshi

AU - Kodama, Kazuhisa

AU - Tanouchi, Jun

AU - Mishima, Masayoshi

AU - Kusuoka, Hideo

AU - Nakatani, Daisaku

AU - Mizuno, Hiroya

AU - Shimizu, Masahiko

AU - Hori, Masatsugu

PY - 2005/10

Y1 - 2005/10

N2 - We conduct a prospective randomized study, the OACIS-LIPID, to determine whether early use of pravastatin can prevent secondary cardiac events in patients with acute myocardial infarction (AMI) and hyperlipidemia (HL). Three hundred and fifty Japanese patients with AMI and mild to moderate HL are randomly assigned to receive or not to receive pravastatin in an open-labeled fashion. The primary dose of pravastatin is 10 mg per day, which is a standard dose for the Japanese population. Both groups receive dietary counseling. Over a 9-month follow-up period, the combination of the endpoints (death, nonfetal myocardial infarction, unstable angina, noncardiac rehospitalization, revascularization and nonfetal stroke) will be evaluated. The results of the OACIS-LIPID study will determine the utility of a practical dose of hydroxymethylglutaryl coenzyme A reductase as an early intervention in AMI.

AB - We conduct a prospective randomized study, the OACIS-LIPID, to determine whether early use of pravastatin can prevent secondary cardiac events in patients with acute myocardial infarction (AMI) and hyperlipidemia (HL). Three hundred and fifty Japanese patients with AMI and mild to moderate HL are randomly assigned to receive or not to receive pravastatin in an open-labeled fashion. The primary dose of pravastatin is 10 mg per day, which is a standard dose for the Japanese population. Both groups receive dietary counseling. Over a 9-month follow-up period, the combination of the endpoints (death, nonfetal myocardial infarction, unstable angina, noncardiac rehospitalization, revascularization and nonfetal stroke) will be evaluated. The results of the OACIS-LIPID study will determine the utility of a practical dose of hydroxymethylglutaryl coenzyme A reductase as an early intervention in AMI.

KW - Acute myocardial infarction

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=29144433349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144433349&partnerID=8YFLogxK

U2 - 10.1159/000089599

DO - 10.1159/000089599

M3 - Article

AN - SCOPUS:29144433349

SN - 1422-9528

VL - 5

SP - 193

EP - 196

JO - HeartDrug

JF - HeartDrug

IS - 4

ER -

Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this